NEW YORK (GenomeWeb) – MiRxes, a Singapore-based life sciences and molecular diagnostics company, has expanded its global activities in recent weeks obtaining a CE-IVD mark for a quantitative PCR-based gastric cancer test, while establishing a US subsidiary and naming distributors to sell its products across Europe, the Middle East, and Asia.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.